虽然在预防和治疗宫颈癌方面取得了进展，但全球发病率和死亡率仍然很高。免疫疗法与标准化疗结合，为进一步获益提供了机会。在这里，我们报告了帕博利珠单抗联合标准化疗和贝伐珠单抗治疗晚期或复发性宫颈癌的药理特性、临床疗效、安全性和耐受性的证据。对于PD-L1表达宫颈癌的恶性转移、复发或进展患者，没有禁忌症进行抗VEGF治疗时，使用帕博利珠单抗与贝伐珠单抗和联合卡铂和紫杉醇的标准化疗是值得的。没有证据支持广泛应用帕博利珠单抗进行治疗，也没有证据支持其用于PD-L1非表达的肿瘤治疗。

Despite progress on prevention and treatment of cervical cancer, global morbidity and mortality remain high. Immunotherapy, in conjunction with standard chemotherapy, presents an opportunity for further benefit.Here we report the pharmacologic properties, evidence for clinical efficacy, safety, and tolerability of pembrolizumab in addition to standard chemotherapy with and without bevacizumab for treatment of advanced or recurrent cervical cancer.In patients with progressive, recurrent, or metastatic PD-L1 expressing cervical cancer, without contraindication to anti-VEGF therapy, the use of pembrolizumab with bevacizumab and standard chemotherapy with carboplatin and paclitaxel is warranted. There is no evidence to support the use of pembrolizumab for this population broadly, and no evidence to support its use in PD-L1 non-expressing tumors.